Whilst leg cramps are not formally listed as a recognised adverse effect in UK product information, patients occasionally report muscle cramping during treatment
Cignas 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity
The observed effect was least pronounced in the BSO-treated group, as shown in western blot
(PubMed) Maglione E, Marrese C, Migliaro E, et al